Methods: Cognitive functions of 79 patients were assessed via Mini Mental Status Examination (MMSE) and Alzheimer's Disease Assessment Scale Cognitive subscale (ADAS-cog). 40 healthy controls (HC) and 39 patients with AD. Levels of serum lipopolysaccharides (LPS), tumor necrosis factor-alpha (TNF-α) and β amyloid protein (Aβ) in plasma were determined by enzyme linked immunosorbent assay (ELISA). mRNA expressions in leukocytes of amyloid protein precursor(APP), presenilin1 (PS1) and β-site APP-cleaving enzyme 1 (BACE1) were determined using real-time PCR. Results: Serum LPS level in patients with AD were significantly higher than that of healthy controls. Proinflammatory analysis showed that serum TNF-α level in patients with AD was prominently elevated in comparison to HC. And the results on the related markers about the formation of Aβ deposition revealed that serum Aβ level and mRNA manifestation levels of APP, PS1, and BACE1 in AD group were significantly higher than that of healthy controls. Correlation analysis showed that the LPS level was significantly positively related to the serum TNF-α and Aβ levels, and APP and BACE1 mRNA expressions in AD patients, while only positively correlated with the Aβ level (r=0.827, p<0.001) and TNF-α level (r=0.780, p<0.001) in plasma, but no correlation with mRNA expressions of APP, PS1, and BACE1(p>0.05). Conclusion: AD patients have the increase of endotoxemia and endotoxemia may upregulate the expression of APP and BACE1 by activating inflammation response with the representation of the elevated TNF-α level in blood. Keywords: Microbiota-gut-brain axis; endotoxemia; Alzheimer's disease; β-amyloid protein; presenilin
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Citalopram Ameliorates Synaptic Plasticity Deficits in Different Cognition-associated Brain Regions Induced by Social Isolation in Middle-Aged Rats
Wei-Gang Gong, School of Medicine, Southeast University, China

Abstract
Our previous experiments demonstrated that social isolation (SI) caused AD-like tau hyperphosphorylation and spatial memory deficits in middle-aged rats. However, the underlying mechanisms of SI-induced spatial memory deficits remains elusive. Middle-aged rats (10 months) were group or isolation reared for 8 weeks. Following the initial four-week period of rearing, citalopram (10 mg/kg i.p.) was administered for 28 days. Then, pathophysiological changes were assessed by performing behavioral, biochemical and pathological analyses. We found that SI could cause cognitive dysfunction and decrease synaptic protein (synaptophysin or PSD93) expression in different brain regions associated with cognition, such as the prefrontal cortex, dorsal hippocampus, ventral hippocampus, amygdala and caudal putamen, but not in the entorhinal cortex or posterior cingulate. Citalopram could significantly improve learning and memory and partially restore synaptophysin or PSD93 expression in the prefrontal cortex, hippocampus and amygdala in SI rats. Moreover, SI decreased the number of dendritic spines in the prefrontal cortex, dorsal hippocampus and ventral hippocampus, which could be reversed by citalopram. Furthermore, SI reduced the levels of BDNF, serine-473-phosphorylated Akt (active form) and serine-9-phosphorylated GSK-3β (inactive form) with no significant changes in the levels of total GSK-3β and Akt in the dorsal hippocampus, but not in the posterior cingulate. Our results suggest that decreased synaptic plasticity in cognition-associated regions might contribute to SI-induced cognitive deficits, and citalopram could ameliorate these deficits by promoting synaptic plasticity mainly in the prefrontal cortex, dorsal hippocampus and ventral hippocampus. The BDNF/Akt/ GSK-3β pathway plays an important role in regulating synaptic plasticity in SI rats. Keywords: Social Isolation · Citalopram · Alzheimer's disease ·Synaptic Plasticity· Spatial Memory
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Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor.
Takashi Kudo, Osaka University, Japan
Abstract
We have recently demonstrated that induction of sigma 1 receptor (Sig-1R) expression is caused by endoplasmic reticulum (ER) stress through the PERK pathway, which is one of the cell's responses to ER stress. In addition, it has been demonstrated that cell death signal transmission can be suppressed by up-regulation of Sig-1R. Fluvoxamine (Flv) is a selective serotonin reuptake inhibitor (SSRI) that it is known to have a high affinity for Sig-1R. In the present study, we have shown that treatment of neuroblastoma cells with Flv induces Sig-1R by directly increasing ATF4 translational regulation without any involvement of PERK pathway. The Flv-mediated induction of Sig-1R prevents neuronal cell death by ER stress. Moreover the ER stress resistance by Flv results in reduction of infarction area due to focal cerebral ischemia in mice. This study shows that Flv, frequently used in clinical practice, has the property of alleviating ER stress suggesting that it can be used as a feasible therapy for cerebral diseases caused by ER stress.
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Distribution of Human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs) in the Alzheimer's Disease Transgenic Mouse after a Single Intravenous Injection significant differences in the amyloid beta protein, Neprilysin (NEP), and SOX2 levels were not observed among the groups. Conclusion: Our study showed that a single dose of 1X10^6 hUCB-MSCs injected intravenously into AD transgenic mice resulted in neither delivery into the brain nor generation of therapeutic benefits via paracrine activity. In order to utilize the intravenous route as an effective delivery route for AD stem cell therapy, it will be crucial to perform additional studies on how to increase the permeability of the BBB and how to decrease the entrapment of cells in organs such as the lung and liver.
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Endothelial-monocyte-activating polypeptide-2 (EMAP-2) may be a novel treatment target of Alzheimer's disease Abstract Inflammation has been raised as a candidate of unifying pathogenesis and a target of disease modifying strategy for Alzheimer's disease(AD). A cytokine, endothelial-monocyteactivating polypeptide-2 (EMAP-2) which amplifies actions of tumor necrosis factor alpha (TNF-alpha), might be an important target, since it is involved in microglial activation and neuronal death. We hypothesize that EMAP-2 is associated with the Alzheimer's disease, and anti-EMAP-2 antibody could have therapeutic effects on cognitive impairment in amyloid betainduced AD model animals.
We investigated the association between the EMAP-2 gene, the -9299A/G polymorphism and cognitive impairment in 641 subjects aged from 60 to 80. In addition, we compared EMAP-2 concentration in peripheral blood among people with AD (n = 30), mild cognitive impairment (n = 29), or normal cognition (n = 27). Finally, we examined the effects of anti-EMAP-2 antibody following injecting it to AD model rats on cognitive function using water maze and passive avoidance tests and on a level of cell death in the brain tissue using TUNEL assay.
We found a significant association between the -9299A/G polymorphism (GG vs AG/AA) of EMAP-2 gene and cognitive impairment. GG homozygote compared to A-allele carriers was related to lower mini-mental status examination score (p = 0.001). In addition, EMAP-2 level was significantly higher in the peripheral blood of people with AD than in that of healthy control group (p = 0.05). In the AD model rats, injection of EMAP-2 antibody improved short-term memory (p < 0.01) and fear memory (p < 0.05), and lowered the levels of neuronal cell death in the brain tissue (p < 0.05) Our results suggested a possible involvement of EMAP-2 in AD pathogenesis, as well as the potential of humanized anti-EMAP-2 antibody as a novel option for AD treatment.
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Disease-modifying therapy through enhancement of neuronal Aß-degrading enzyme neprilysin activity for Alzheimer's disease Nobuhisa Iwata, Masashi Asai, Daisuke Hatta, Mikako Honda, Yuma Hori, Momoka Kinoshita, Naotaka Kuroda, Kaname Ohyama, Keiro Shirotani, Takashi Tanaka, Kaori Watanabe Nagasaki University, Japan Abstract Aggregation and deposition of amyloid-β peptide (Aβ) in the brain are triggering events of the long-term pathological cascade of Alzheimer's disease (AD), and are closely associated with the metabolic balance between Aβ anabolic and catabolic activities. As almost all familial AD mutations cause an increase in the anabolism of a particular form of Aβ, Aβ 1-42 , leading to Aβ deposition and accelerating AD pathology, a chronic reduction in the catabolic activity would also promote Aβ deposition. Neprilysin is a rate-limiting peptidase involved in brain Aβ catabolism. Mounting evidence that expression levels of neprilysin are decreased in the hippocampus and cerebral cortex of AD patients from the early stages of disease development and also with aging in humans, suggests a close association of neprilysin with the etiology and pathogenesis of AD. Thus, a subtle but long-term decline in neprilysin activity appears to be at least partly responsible for the memory-related symptoms of AD, and up-regulation of neprilysin would be a promising strategy for disease-modifying therapy of AD.
We screened a compound modulating brain neprilysin activity and/or gene expression using a natural product library, and found that catechins, such as EGCg were capable of up-regulating neprilysin via gene expression. However, their bioavailabilities and blood-brain barrier permeability are not always so good, because these compounds are highly hydrophilic. So, we synthesized aliphatic catechin derivatives by introducing an alkyl chain or aliphatic moiety into EGCg to increase Log P values. Interestingly, some of the aliphatic catechin derivatives more strongly up-regulated not only neprilysin but also α-secretase, which acts to preclude Aβ production, than EGCg did. The aliphatic catechins would be promising drug candidates for therapy and prevention of AD. Currently, we are analyzing their in vivo effects on up-regulation of neprilysin.
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Alteration of neuronal nitric oxide synthase dimerization contributes to the development of Alzheimer's disease 
